Mitochondrial respiration in blood platelets of depressive patients

Mitochondrion

Volumn 13, Issue 6, 2013, Pages 795-800

  Hroudová, Jana ^a   Fišar, Zdeněk ^a   Kitzlerová, Eva ^a   Zvěřová, Martina ^a   Raboch, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Blood platelet; Depressive disorder; Mitochondrion; Respiratory rate

Indexed keywords

AGOMELATINE; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; ARTICLE; BREATHING RATE; CELL PERMEABILIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; ELECTRON TRANSPORT; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; THROMBOCYTE;

BLOOD PLATELET; DEPRESSIVE DISORDER; MITOCHONDRION; RESPIRATORY RATE;

BLOOD PLATELETS; CELL MEMBRANE PERMEABILITY; DEPRESSION; HUMANS; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION;

EID: 84887023852     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2013.05.005     Document Type: Article

References (43)

1. Abdel-Razaq W., Kendall D.A., Bates T.E. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem. Res. 2011, 36:327-338.
2. Ben-Shachar D., Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 2008, 3:e3676.
3. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
4. Calabrese V., Bates T.E., Stella A.M. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem. Res. 2000, 25:1315-1341.
5. Calabrese V., Cornelius C., Dinkova-Kostova A.T., Calabrese E.J., Mattson M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 2010, 13:1763-1811.
6. Cannino G., Di Liegro C.M., Rinaldi A.M. Nuclear-mitochondrial interaction. Mitochondrion 2007, 7:359-366.
7. Diab Y.A., Thomas A., Luban N.L., Wong E.C., Wagner S.J., Levy R.J. Acquired cytochrome C oxidase impairment in apheresis platelets during storage: a possible mechanism for depletion of metabolic adenosine triphosphate. Transfusion 2012, 52:1024-1030.
8. Fattal O., Budur K., Vaughan A.J., Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006, 47:1-7.
9. Fattal O., Link J., Quinn K., Cohen B.H., Franco K. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr. 2007, 12:429-438.
10. 1H MRS study. Bipolar Disord. 2007, 9:119-127.
11. Gardner A., Boles R.G. Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc. Med. 2008, 2:7.
12. Gardner A., Boles R.G. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:730-743.
13. Gardner A., Johansson A., Wibom R., Nennesmo I., von Döbeln U., Hagenfeldt L., Hällström T. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J. Affect. Disord. 2003, 76:55-68.
14. Gnaiger E. Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. Int. J. Biochem. Cell Biol. 2009, 41:1837-1845.
15. Hirschfeld R.M. Screening for bipolar disorder. Am. J. Manag. Care 2007, 13:S164-S169.
16. Hirschfeld R.M., Montgomery S.A., Aguglia E., Amore M., Delgado P.L., Gastpar M., Hawley C., Kasper S., Linden M., Massana J., Mendlewicz J., Möller H.J., Nemeroff C.B., Saiz J., Such P., Torta R., Versiani M. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry 2002, 63:826-837.
17. Horan M.P., Pichaud N., Ballard J.W. Review: quantifying mitochondrial dysfunction in complex diseases of aging. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:1022-1035.
18. Hroudova J., Fisar Z. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol. Lett. 2010, 31:336-342.
19. Hroudová J., Fišar Z. Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin. Neurosci. 2011, 65:130-141.
20. Hroudová J., Fišar Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol. Lett. 2012, 213:345-352.
21. Jou S.H., Chiu N.Y., Liu C.S. Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med. J. 2009, 32:370-379.
22. 31P-magnetic resonance spectroscopic findings to their molecular mechanisms. Int. Rev. Neurobiol. 2005, 63:21-40.
23. Kato T. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 2008, 44:92-102.
24. Kuznetsov A.V., Schneeberger S., Seiler R., Brandacher G., Mark W., Steurer W., Saks V., Usson Y., Margreiter R., Gnaiger E. Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1633-H1641.
25. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacol. 2012, 20:127-150.
26. Morava E., Gardeitchik T., Kozicz T., de Boer L., Koene S., de Vries M.C., McFarland R., Roobol T., Rodenburg R.J., Verhaak C.M. Depressive behaviour in children diagnosed with a mitochondrial disorder. Mitochondrion 2010, 10:528-533.
27. Neustadt J., Pieczenik S.R. Medication-induced mitochondrial damage and disease. Mol. Nutr. Food Res. 2008, 52:780-788.
28. Parikh S., Saneto R., Falk M.J., Anselm I., Cohen B.H., Haas R. A modern approach to the treatment of mitochondrial disease. Curr. Treat. Options Neurol. 2009, 11:414-430.
29. Pesta D., Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol. Biol. 2012, 810:25-58.
30. Raboch J., Anders M., Hellerová P., Uhlíková P. Psychiatrie: doporučené postupy psychiatrické péče III 2010, Tribun EU, Brno.
31. Regenold W.T., Pratt M., Nekkalapu S., Shapiro P.S., Kristian T., Fiskum G. Mitochondrial detachment of hexokinase 1 in mood and psychotic disorders: implications for brain energy metabolism and neurotrophic signaling. J. Psychiatr. Res. 2012, 46:95-104.
32. Reinecke F., Smeitink J.A., van der Westhuizen F.H. OXPHOS gene expression and control in mitochondrial disorders. Biochim. Biophys. Acta 2009, 1792:1113-1121.
33. Renner K., Amberger A., Konwalinka G., Kofler R., Gnaiger E. Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemia cells. Biochim. Biophys. Acta 2003, 1642:115-123.
34. Rezin G.T., Cardoso M.R., Gonçalves C.L., Scaini G., Fraga D.B., Riegel R.E., Comim C.M., Quevedo J., Streck E.L. Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem. Int. 2008, 53:395-400.
35. Shao L., Martin M.V., Watson S.J., Schatzberg A., Akil H., Myers R.M., Jones E.G., Bunney W.E., Vawter M.P. Mitochondrial involvement in psychiatric disorders. Ann. Med. 2008, 40:281-295.
36. Sjövall F., Morota S., Hansson M.J., Friberg H., Gnaiger E., Elmér E. Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis. Crit. Care 2010, 14:R214.
37. Srere P.A. Citrate synthase: [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]. Methods Enzymol. 1969, 13:3-11.
38. Stadlmann S., Renner K., Pollheimer J., Moser P.L., Zeimet A.G., Offner F.A., Gnaiger E. Preserved coupling of oxidative phosphorylation but decreased mitochondrial respiratory capacity in IL-1β-treated human peritoneal mesothelial cells. Cell Biochem. Biophys. 2006, 44:179-186.
39. Starkov A.A. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann. N. Y. Acad. Sci. 2008, 1147:37-52.
40. Steinlechner-Maran R., Eberl T., Kunc M., Schröcksnadel H., Margreiter R., Gnaiger E. Respiratory defect as an early event in preservation-reoxygenation injury of endothelial cells. Transplantation 1997, 63:136-142.
41. Stork C., Renshaw R.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005, 10:900-919.
42. Telford J.E., Kilbride S.M., Davey G.P. Complex I is rate-limiting for oxygen consumption in the nerve terminal. J. Biol. Chem. 2009, 284:9109-9114.
43. van den Heuvel L.P., Smeitink J.A., Rodenburg R.J. Biochemical examination of fibroblasts in the diagnosis and research of oxidative phosphorylation (OXPHOS) defects. Mitochondrion 2004, 4:395-401.